Merger control alongside investment screening: step by step means running two approval tracks in parallel, not one after the other: a competition clearance from Sweden's competition authority, and a foreign direct investment screening decision, each with its own trigger and deadline. Neither substitutes for the other, closing waits for both, and the timetable is set by whichever track is slower.
Who this concerns
The overlap matters to anyone structuring an acquisition, merger or significant shareholding change where the target, or a company it controls, operates in Sweden and meets either a turnover-based competition threshold or falls within a sector treated as sensitive for security or public order purposes. That covers strategic buyers acquiring a competitor or a supplier, private equity funds doing an add-on where the platform company already holds Swedish assets, and industrial groups consolidating a fragmented market through smaller deals that individually look modest but collectively raise concentration.
Boards approving the transaction need to know before signing, not after, whether both regimes apply, because the answer changes what goes into the purchase agreement: conditions precedent, long-stop dates, break fees and who carries the risk of a prohibition or a blocking order.
The foreign element changes the analysis in a specific way. Where the acquirer, or its ultimate parent, sits outside Sweden, or outside the EU and EEA, the investment screening question is asked with a different starting assumption than the competition question. Competition law looks at overlap in the Swedish market regardless of where the buyer is incorporated. Investment screening looks first at who ultimately controls the acquiring entity, and whether that control sits with a state, a state-linked body, or an investor outside the EU and EEA, because that is the factor the regime is built to capture. A Swedish buyer acquiring a Swedish target can trigger competition review and stay entirely outside screening. A foreign buyer acquiring a small Swedish target that would never meet a competition threshold can still trigger a mandatory screening filing purely because of what the target does, not how big it is.
What the law says
Under Swedish law as it currently stands, two independent regimes run alongside each other whenever a transaction has both a competition dimension and a national security or public order dimension. Neither regime defers to the other, and clearance under one creates no presumption in the other.
The first is merger control under Swedish competition law, enforced by the Swedish Competition Authority (Konkurrensverket). It applies where the parties meet the turnover-based thresholds set out in the current text of the Competition Act, and it is triggered by the transaction itself: an acquisition of control, a merger, or a joint venture performing the functions of an autonomous economic entity. Notification is mandatory once the thresholds are met, and completing the transaction before clearance, where a mandatory filing obligation exists, is itself a breach capable of being sanctioned independently of the outcome of the substantive review.
The second is the screening of foreign direct investment, enforced by the Inspectorate of Strategic Products (ISP). It applies to entities carrying out activities that the current legislation treats as sensitive from a security or public order standpoint, and the trigger is different from merger control: it is not about market overlap or turnover, it is about the nature of the target's activity and the origin of the acquirer's controlling interest. Where the activity falls within scope, notification duties can arise regardless of deal size, and in some categories the obligation sits with the target as much as with the acquirer. Neither regime waives itself because the other has cleared the deal.
How it works in practice
Step 1: Confirm which regimes are actually triggered
The first task is scoping, not filing. For competition, that means running the parties' turnover against the thresholds in the current text of the Competition Act and checking whether the transaction meets the legal definition of a concentration, as distinct from a minority stake carrying no control. For screening, that means classifying what the target actually does, because a target that looks like an ordinary manufacturer on paper can fall within scope because of a single contract, facility or piece of infrastructure it operates.
Step 2: Map the two filing tracks against each other
Once both triggers are confirmed, the tracks are mapped side by side: which authority receives which filing, what starts the clock for each, whether pre-notification contact is available, and what sequencing is realistic given that the two authorities do not coordinate their timetables with each other. This map becomes the transaction timetable, not a separate compliance annex to it.
Step 3: Build the notification for the competition authority
The competition filing sets out the parties, the structure of the transaction, the affected markets, and the competitive assessment, including any efficiencies the parties want on the record from the outset rather than introduced later in response to a request for information. Incomplete filings do not start the clock; they are returned or treated as not validly made, which is the most common source of avoidable delay in this track.
Step 4: Build the notification for the screening authority
The screening filing is built around a different question: what the target does, who will control it after closing, and where that controlling interest ultimately sits. Ownership charts need to go past the immediate buyer to the entity that actually exercises control. Where the target's activity touches infrastructure, supply to public bodies, or dual-use capability, the filing needs to address that directly rather than leave the authority to infer it.
Step 5: Run pre-notification contacts before filing formally
Both authorities allow, and in practice expect, informal contact before a formal notification, particularly where the scope question is not clear-cut. Using that contact to test the authority's initial view on scope or on the completeness of a draft filing is cheaper than finding out, after a formal clock has already started, that the filing is incomplete or the classification is disputed.
Step 6: Manage the parallel review periods
Once both filings are in, the two clocks run independently. A first-phase clearance in one track has no bearing on where the other track stands. Deal teams need a single tracking document showing both deadlines and both triggers for extension, because a pause in one process does not pause the transaction timetable generally.
Step 7: Handle a request for remedies or conditions
Where either authority raises concerns, the response has to be built with the other process in view. A structural remedy offered to satisfy a competition concern, such as a divestment, can itself raise a fresh screening question if the buyer of the divested business is subject to screening in its own right. A condition imposed under screening can affect the competitive assessment of the remaining business. Remedies are not negotiated with each authority in isolation.
Step 8: Set closing conditions that reflect both clearances
The purchase agreement needs conditions precedent that reference both clearances by name, not a single generic "regulatory clearance" condition, because the consequences of a prohibition differ between the two regimes, and the long-stop date needs to reflect the slower of the two realistic timetables, not the faster one.
What to check before signing:
- Whether the transaction meets the legal definition of a concentration, as distinct from a minority investment.
- Whether the target's activity, or that of any controlled subsidiary, falls within a category treated as sensitive under the current screening regime.
- Who ultimately controls the acquiring entity, tracing through any holding structure to the entity exercising real control.
- Whether either filing obligation sits with the target rather than, or in addition to, the acquirer.
- Whether the transaction documents allow completion to be delayed for as long as either clearance realistically requires, without triggering a break fee.
Does investment screening clearance replace merger control clearance?
No. The two regimes ask different questions and are enforced by different authorities, and clearance, or the absence of any objection, under one carries no legal weight in the other. A transaction that raises no competition concern can still be blocked, delayed or made conditional under screening, and a transaction cleared under screening can still face a full competition investigation. Both tracks have to be run, and both have to conclude, before completion.
Can the two notifications be filed at the same time?
Generally yes, and in most cases that is the more efficient sequencing, since no rule requires one clearance before the other can be sought. The real constraint is not timing permission, it is content: each filing needs to be complete and internally consistent with what the other authority has been told, since both authorities can, and sometimes do, ask about the other process.
What happens if only one of the two regimes applies?
Then only that track needs to run, but the scoping work to reach that conclusion still has to be done and documented. The assumption that a deal is "too small" for competition or "not sensitive" for screening is exactly the assumption that produces a late-discovered filing obligation after signing, when the options for managing the timetable are far more limited than before signing.
The numbers
Both regimes set their deadlines and thresholds by reference to the current text of the relevant legislation, and those figures are revised from time to time, which is why this material does not reproduce specific turnover thresholds or day counts as if they were fixed. What can be said with confidence is the structure: competition review runs in an initial phase, during which the authority decides whether the transaction can be cleared without further investigation, followed by an in-depth phase if concerns are identified, each phase having its own deadline and its own triggers for extension, most commonly a request for further information. Screening review follows a broadly similar shape: an initial period in which the authority decides whether to open an in-depth assessment, followed by a longer period if it does, with extension possible where the case is complex.
The practical consequence for a transaction timetable is that the longer of the two realistic periods, not the shorter, should set the long-stop date, and the internal deal timeline should build in an extension scenario for at least one of the two tracks as the base case, because a request for further information is a routine event in both processes rather than a sign that the transaction is in difficulty.
Where it usually goes wrong
The most common failure is treating one clearance as covering the field. Deal teams that have run competition clearances before sometimes assume the screening filing is a formality layered on top of a process they already understand, and under-resource it accordingly. The two filings ask for different information and are decided against a different statutory test, and a filing prepared as an afterthought reads that way to the authority reviewing it.
A second failure is miscounting who the acquirer actually is for screening purposes. A transaction structured through a Swedish or EU holding vehicle can still trigger screening if the ultimate controlling interest behind that vehicle sits outside the EU and EEA. Structuring the acquisition through an intermediate entity does not, by itself, take the transaction outside scope, because authorities look through the immediate buyer to the entity that exercises control.
A third failure is assuming that a remedy accepted in one process will be accepted, or even understood, by the other authority without separate engagement. A divestment package agreed to resolve a competition concern can introduce a new acquirer who is themselves subject to screening, and a condition imposed under screening can alter the competitive landscape the competition authority has already assessed. Running the two remedy discussions as unrelated is where otherwise well-managed transactions lose weeks late in the process.
None of this means both regimes always apply, or that the analysis is always close. Many transactions clear both thresholds easily, or clear neither, and the scoping work above is what establishes that with confidence rather than assumption. Where a transaction is genuinely below both thresholds, this sequence collapses to a single confirmatory memo, and that is itself a legitimate result of doing the analysis properly.
What to do next
Everything above can be done by an in-house team with access to the current text of both regimes: scoping the triggers, mapping the two tracks, and building the transaction timetable around the slower of them. Where the self-directed work stops is the point at which the actual facts of a specific transaction, the target's real activity, the identity of the ultimate controller, the shape of a proposed remedy, need to be checked against the current text of the law rather than against a general description of how the process works. That check is what an assessment of the transaction covers.
Deals that reach closing under this kind of dual clearance often turn on a board resolution taken to approve the transaction or a related remedy, and where that resolution is later challenged, the exposure is analysed separately in what makes a board resolution invalid. Both filings, and the wider transaction structure, sit within the firm's corporate investment screening practice.